Investor Presentaiton

INVESTOR 20 DAY 23 The power of genomic and epigenomic data is amplified by connections to real-world evidence GUARDANTINFORM >90% TM of commercial samples are linked to associated medical claims data1 Comorbidities Lines of therapy Treatment history ☆ Disease progression Time to next treatment × Treatment discontinuation Survival GUARDANT™ 1. Guardant INFORM database, Q3 2023 158

View entire presentation